ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Morgan Stanley Upgrades ResMed (RMD) to Overweight
July 31, 2015 10:01 AM EDTMorgan Stanley upgraded ResMed (NYSE: RMD) from Equalweight to Overweight.
For an analyst ratings summary and ratings history on ResMed click here. For more ratings news on ResMed click here.
Shares of ResMed closed at $56.12 yesterday.
... MoreResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4
July 31, 2015 8:02 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on ResMed (NYSE: RMD) to $66.00 (from $65.00) following solid Q4 results driven by flow generator product cycle.
Matson commented, "RMD's revenue and EPS beat consensus as its revenue... More
Deutsche Bank Downgrades ResMed (RMD) to Sell
July 31, 2015 7:32 AM EDTDeutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.
"After the incredible success of ResMeds AirSense range we are wary FY16... More
ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats
July 30, 2015 4:52 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More